The market for cardiac valvulotome consists of medical equipment used for cutting and extracting damaged heart valves. Cardiac valvulotomes assist in the execution of basic cardiovascular treatments including heart valve repair and balloon valvuloplasty. Some key product types include flexible valvulotomes, rigid valvulotomes, disposable valvulotomes, and cutting sheaths. Increasing demand for minimally invasive procedures and growing geriatric population suffering from valvular heart diseases are major drivers for this market.
The Global cardiac valvulotome market is estimated to be valued at US$ 157.2 Mn in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period 2024 to 2031.
Market Dynamics
The market is anticipated to rise as aortic stenosis becomes more common.
Aortic stenosis is a disorder that causes the aortic valve to narrow and obstruct the flow of blood from the heart's left ventricle to the rest of the body. Using a cardiac valvulotome can help treat this problem. In cases of severe aortic stenosis, a valvulotome can be used to perform a valvulotomy operation when surgical intervention is required.
The aortic valve's bulky or fused leaflets are precisely sliced during this surgical treatment to increase the valve's openness. Breathlessness and chest pain are temporarily relieved as a result of the improved valve's flexibility and decreased cardiac pressure. But it might
Key Takeaways
Key players operating in the Cardiac Valvulotome Market Size are LeMaitre, INVAMED, GeoSurgical, LimFlow, Inc., B. Braun SE, Teleflex Incorporated, StarFish Product Engineering Inc., Koven Technology Canada Inc., Andramed, Zgrum Medical, BD, PEAK SURGICAL, and Symmetry Surgical Inc. The rising incidence of cardiovascular diseases including rheumatic heart disease and calcific aortic stenosis has increased the demand for cardiac valvulotome procedures. Additionally, growing geriatric population who are more prone to developing valvular problems is also contributing to market growth. Major companies are expanding their product portfolios and presence globally especially in emerging regions of Asia Pacific and Latin America to tap the increasing opportunities.
Market drivers
One of the key drivers for the cardiac valvulotome market is the rising prevalence of cardiovascular diseases worldwide. Conditions such as valvular heart disease, coronary artery disease and rheumatic heart disease are becoming more common due to changing lifestyle diseases and increasing life expectancy. According to the World Health Organization, cardiovascular diseases account for over 17.9 million deaths annually across the globe. This increasing burden of heart conditions will significantly drive the need for cardiac valvulotome procedures and devices over the forecast period.
The current geopolitical situation is impacting the growth of the cardial valvulotome market. Political instability and economic uncertainties in various parts of the world are influencing healthcare spending and demand for different medical devices. The global supply chain disruptions due to the Russia-Ukraine conflict and trade tensions between some countries are posing challenges in the procurement of raw materials and components. This is hindering the production scale and output for key market players.
Moreover, economic sanctions imposed by different nations are restricting business opportunities in certain geographical locations. For sustained growth in the long run, companies need to diversify their manufacturing operations and supplier networks globally. They must also focus on innovating products that offer superior clinical outcomes to generate more demand even during difficult economic conditions. Developing versatile devices compatible with various interventional techniques can further boost the adoption rate.
North America currently dominates the cardiac valvulotome market in terms of value. This is attributed to factors such as the rising prevalence of valvular heart diseases, growing geriatric population, high healthcare spending, reimbursement coverage for interventional procedures, and presence of many global industry leaders. Within the region, the United States holds the largest market share and is expected to witness significant growth over the forecast period.
Asia Pacific is poised to showcase the fastest growth in the cardiac valvulotome market owing to improving access to advanced treatments, increasing medical tourism, rising healthcare investments, and expansion strategies of major industry participants to tap opportunities in emerging nations. China, Japan and India will drive the regional market growth through rapid urbanization, rising incomes, growing disease awareness, and expanding medical infrastructure.
Over the forecast years, the cardiac valvulotome market in Europe is projected to showcase steady expansion endorsed by evolving reimbursement policies, encouraging regulations, and technological advancements for transcatheter procedures. However, economic turmoil in some parts of Eastern Europe may negatively impact the regional growth momentum to a certain extent. Latin America and Middle East & Africa have considerable growth potential for valvulotome devices, and multinational companies are focusing on penetrating these developing markets through collaborations with local players.
Get more insights on Cardiac Valvulotome Market
Also read related article on Cardiac Valvulotome Market
Comments
0 comment